Arbutus Biopharma Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABUS research report →
Companywww.arbutusbio.com
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
- CEO
- Lindsay Androski
- IPO
- 2007
- Employees
- 44
- HQ
- Warminster, PA, US
Price Chart
Valuation
- Market Cap
- $863.24M
- P/E
- 5.27
- P/S
- 4.51
- P/B
- 3.25
- EV/EBITDA
- 5.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.98%
- Op Margin
- 80.79%
- Net Margin
- 83.95%
- ROE
- 129.32%
- ROIC
- 56.72%
Growth & Income
- Revenue
- $14.08M · 128.21%
- Net Income
- $-33,501,000 · 52.09%
- EPS
- $-0.17 · 55.26%
- Op Income
- $-27,051,000
- FCF YoY
- 39.05%
Performance & Tape
- 52W High
- $5.10
- 52W Low
- $3.04
- 50D MA
- $4.37
- 200D MA
- $4.32
- Beta
- 0.62
- Avg Volume
- 2.15M
Get TickerSpark's AI analysis on ABUS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 2, 26 | Nguyen Tuan | other | 188,400 |
| Feb 2, 26 | Nguyen Tuan | other | 73,500 |
| Feb 2, 26 | Androski Lindsay | other | 71,700 |
| Feb 2, 26 | Androski Lindsay | other | 28,000 |
| Aug 4, 25 | Sawhney Roger | other | 157,600 |
| Aug 4, 25 | Sawhney Roger | other | 0 |
| Mar 31, 25 | Nguyen Tuan | other | 750,000 |
| Mar 31, 25 | Nguyen Tuan | other | 750,000 |
| Mar 28, 25 | Nguyen Tuan | other | 0 |
| Mar 18, 25 | Hasija Anuj | other | 157,600 |
Our ABUS Coverage
We haven't published any research on ABUS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABUS Report →